What Institut Gustave Roussy does

Institut Gustave Roussy is a privately-held, non-profit comprehensive cancer center founded in 1926 and headquartered in Villejuif, France, recognized as a public utility organization and statutorily designated Centre de Lutte Contre le Cancer (CLCC). It combines clinical oncology (surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, interventional radiology), translational and fundamental research, and university-level education in oncology under a single institution, and is ranked #1 in Europe and France and #4 globally by Newsweek's World's Best Specialized Hospitals 2026. The institute treats 4,200+ patients annually across 50,000+ sessions, serves pediatric, AYA, adult, oncogeriatric, and international patient segments, and is staffed by 4,000+ professionals (3,200+ at the Villejuif main site and additional staff at the Hôpital de Chevilly-Larue satellite).

Its product surface is anchored on distinctive clinical programs and proprietary technologies: the FRESH liquid biopsy genomic profiling program open nationally; deep-learning AI-assisted colonoscopy (>1,000 procedures/year, 10-15% improvement in polyp detection); the ZAP-X gyroscopic radiosurgery platform; Papillon+ contact radiotherapy; the only French hospital pharmacy implementing semi-solid extrusion 3D printing for personalized multi-drug capsules; the OncoLum photobiomodulation center; the single-port da Vinci robotic surgery system; and the Interception personalized prevention programme. Research output is institutionalized through 107 presentations at ASCO 2026, an annual Gustave Roussy Prize of €200,000, and an emerging technology-transfer pipeline that has produced spin-offs Signadori Bio (with Sofinnova Partners, March 2025) and exclusive licensing to Kahimmune Therapeutics (February 2026).

Revenue mechanics blend four streams: (1) French national health system (Sécurité sociale) reimbursement for clinical services delivered to public patients; (2) donations, regular giving, legacies, and SMS donations through a 'Don en Confiance'-certified fundraising operation; (3) corporate sponsorships, philanthropy, and pharmaceutical partnerships; and (4) technology transfer and licensing income from research discoveries (including spin-off equity). International expansion is executed through Gustave Roussy International, with Gustave Roussy International Egypt (300+ beds) opened in Cairo on April 8, 2025, via a brand-license JV with Elevate P.E. International patient services, the Cancer Core Europe network, and a Transatlantic Exchange with Dana-Farber anchor a multi-channel go-to-market that combines direct-to-consumer patient portals, enterprise-scale referrals, and event-driven awareness campaigns (Mars Bleu, Septembre en Or, ASCO/ESMO presence).

Name

Institut Gustave Roussy

Legal name

Gustave Roussy

Website

https://gustaveroussy.fr

Company type

Private

Founded year

1926

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Institut Gustave Roussy is Europe's #1 cancer center, founded in 1926 in Villejuif, France, combining comprehensive oncology care, translational research, and education across pediatric, adult, and geriatric patient segments with international licensing for branded cancer centers.

Ownership category

akta.pro rank

Product category

Comprehensive Cancer Center Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), General Medical and Surgical Hospitals (622110), Offices of Physicians (62111)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Comprehensive cancer treatment
• Oncology research institute
• Personalized cancer therapy
• Clinical trials oncology
• Radiation therapy services

Headquarters

HQ city

Villejuif

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Healthcare Services (French National Health System): Gustave Roussy operates as a recognized public healthcare institution in France. Revenue is generated through reimbursement by the French national health insurance system (Sécurité sociale) for patient treatments, consultations, hospitalizations, and procedures. As a Centre de Lutte Contre le Cancer (CLCC), it receives institutional funding and patient payments covered through national health coverage.
2. Donations and Legacies: The institute raises funds from individuals through online donations, regular giving, targeted donations, legacy bequests, life insurance donations, and SMS donations. Gustave Roussy and its Fondation are authorized to receive donations and are labeled 'Don en Confiance' since 2009 for transparency.
3. Fondation Gustave Roussy – Research Funding: The Fondation Gustave Roussy (transformed into a Fondation de recherche in 2023) collects funds to finance research at Gustave Roussy, conducts its own research and training programmes, and is habilitated to receive donations and legacies.
4. Sponsorships and Corporate Partnerships: The institute generates revenue through corporate sponsorship and patronage (mécénat), including pharmaceutical partnerships, equipment agreements, and international licensing of the Gustave Roussy brand.
5. Technology Transfer and Licensing: Gustave Roussy licenses discoveries in immunology and oncology to biotech companies (e.g., Kahimmune Therapeutics for dark genome discoveries), generating revenue through exclusive licensing agreements and spin-off equity.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Gustave Roussy is a comprehensive cancer center delivering multi-modality oncology care (surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, interventional radiology) combined with translational research, clinical trials, and medical education. It runs proprietary programs including FRESH liquid-biopsy genomic profiling, AI-assisted colonoscopy, ZAP-X radiosurgery, Papillon+ contact radiotherapy, 3D-printed personalized medicines, and the Interception personalized prevention program, serving adult, pediatric, oncogeriatric, and international patient populations across its Villejuif campus, Chevilly-Larue satellite, and licensed center in Egypt.

Product overview

Institut Gustave Roussy operates as a comprehensive cancer center offering a portfolio of distinct clinical programs, AI-powered diagnostic tools, and therapeutic technologies rather than a unified platform-plus-modules architecture. Core offerings include the GrayOS care orchestration platform for radiation therapy optimization, the FRESH liquid biopsy genomic profiling program, AI-assisted colonoscopy detection tools, the OncoLum photobiomodulation center, the ZAP-X radiosurgery platform, and the DOSELIA AI pediatric radiotherapy research project. Gustave Roussy also partners on AI-driven products including BRCAura for pathology-based BRCA screening and One Biosciences single-cell analysis, participates in clinical trials such as IMMUNOLIFE and EGL-001, and provides screening/prevention programs including Colodépist and the Interception personalized prevention program.

Differentiator

Problem solved

Functional benefit

Products and services

• Comprehensive Multi-Modality Cancer Treatment Program Multi-modality oncology care combining surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, and interventional radiology for adult patients across all tumor types (brain, breast, colorectal, lung, prostate, gynecological, hematological, skin, head and neck, sarcoma, etc.).
• Pediatric, Adolescent and Young Adult (AYA) Oncology Program Specialized pediatric and adolescent/young adult oncology program offering age-appropriate treatment protocols, schooling continuity services, long-term follow-up care, and psychological support for young patients and families.
• Oncogeriatrics Program Specialized geriatric oncology program for elderly cancer patients, including comprehensive geriatric evaluation, adapted treatment protocols, and management of frailty, comorbidities and polypharmacy.
• FRESH Liquid Biopsy Genomic Profiling Program Genomic profiling via liquid biopsy open to all patients in France, delivering personalized therapeutic proposals including access to innovative treatments based on molecular tumor profiles.
• International Patients Service Dedicated division providing appointments, medical second opinions, and coordinated care for cancer patients from outside France, with multilingual intake and cross-border care coordination.
• Early-Phase and Standard Clinical Trials Program Sponsored and investigator-initiated oncology clinical trials across phases (including early-phase/Phase 1/2), such as the IMMUNOLIFE Phase 2 NSCLC trial and the EGL-001 Phase 1/2 head and neck squamous cell carcinoma trial, providing patient access to experimental therapies.
• Supportive and Palliative Care Program (including OncoLum photobiomodulation) Comprehensive supportive care services including psychological support, pain management, addictology, nutrition, rehabilitation, palliative care, and the OncoLum photobiomodulation center (red/near-infrared light therapy) for treatment side effects such as oral mucositis.
• Interception Personalized Cancer Prevention Program Personalized prevention program targeting high-risk individuals, including screening pathways, AI-assisted colonoscopy and the dedicated Colodépist pathway for colorectal cancer detection in adults under 50.
• 3D-Printed Personalized Drug Capsules Service Hospital-pharmacy-based 3D printing of personalized multi-drug capsules for cancer patients in clinical trials, enabling customized dosage combinations in a single dosage form.
• Gustave Roussy International Egypt (licensed oncology center) Licensed Gustave Roussy-branded oncology center in Cairo operated under partnership with Elevate P.E., with capacity over 300 beds and priority on hematology and breast cancer care.

Quantifiable outcome

• 4,200+ patients treated in 2025 across 50,000+ treatment sessions
• +7 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature10 records

Partnerships

16 partnerships are on record, tiered core and flagship.

• One BiosciencescoreStrategic or Co-development Partner · 19 May 2026Gustave Roussy partnered with One Biosciences to implement single-cell analysis into clinical oncology practice using AI-powered solutions for predicting treatment responses in cancer patients. The collaboration builds on previous feasibility studies, integrating ultra-high-resolution tumor data into patient care workflows.
• Gray Oncology SolutionscoreTechnology or Integration · 19 May 2026Gray Oncology Solutions deployed its GrayOS care orchestration platform at Gustave Roussy, making it the first European institution to adopt the technology for radiation therapy optimization. The platform integrates with existing clinical systems to optimize appointment planning, reduce manual coordination, and improve machine utilization, reporting 5-15% increase in patients treated and 80% reduction in coordination time.
• StarkAge TherapeuticscoreStrategic or Co-development Partner · 16 April 2026StarkAge Therapeutics will present preclinical data on STX-1, its first-in-class DPP4-targeting antibody-drug conjugate for solid tumors, at AACR 2026. Studies conducted in collaboration with Gustave Roussy Institute demonstrate strong target affinity, target-dependent cytotoxicity, and enhanced antitumor activity in senescent cell-enriched tumors. STX-1 progressing toward IND-enabling studies.
• Egle Therapeutics (consortium: University College London, Vall d'Hebron Institute of Oncology, Technical University of Dresden)flagshipStrategic or Co-development Partner · 2 March 2026Egle Therapeutics awarded ~€8 million by Horizon Europe for clinical development of EGL-001 (anti-CTLA-4 x IL-2m fusion protein) in neoadjuvant head and neck squamous cell carcinoma. Gustave Roussy is one of four European scientific institutions in the consortium conducting a multicenter Phase 1/2 trial with translational research incorporating multi-omics profiling, immune monitoring, and AI-driven pathomics modeling.
• Lytix BiopharmacoreStrategic or Co-development Partner · 17 February 2026Lytix Biopharma published a comprehensive review on oncolytic peptides in the Journal of ImmunoTherapy of Cancer (JITC), developed in collaboration with Institut Gustave Roussy and Fox Chase Cancer Center. Highlights clinical data for ruxotemitide (LTX-315/VP-315) showing complete and lasting responses in BCC patients and significant activity in cold tumors.
• Kahimmune TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 3 February 2026Kahimmune Therapeutics, a spin-off from Gustave Roussy and SATT Paris-Saclay, signed an exclusive licensing agreement to commercialize discoveries in immunology relating to the dark genome. Access to the Kahinomics™ platform and Kahigens™ neoantigens with plans to develop shared mRNA cancer vaccines targeting colorectal and pancreatic cancers. Seed funding round underway.
• MaaT PharmacoreStrategic or Co-development Partner · 20 January 2026Gustave Roussy sponsored the IMMUNOLIFE Phase 2 clinical trial evaluating MaaT Pharma's gut microbiome therapy MaaT033 combined with Regeneron's Cemiplimab for advanced NSCLC patients who developed resistance to immunotherapy following antibiotic exposure. 162 patients across 14 centers in France. Interim futility analysis expected H1 2027, primary results in late 2030.
• OwkinflagshipStrategic or Co-development Partner · 18 November 2025At the Franco-German Digital Sovereignty Summit in Berlin, Owkin together with Gustave Roussy and Charité announced Europe's first pan-European agentic infrastructure for biology, designed to make biomedical data AI-ready and accelerate drug development. Combining agentic AI systems with biomedical data structuring to power a reasoning model automating and augmenting biological research stages.
• Dana-Farber Cancer InstituteflagshipStrategic or Co-development Partner · 11 April 2025Annual Transatlantic Exchange scientific conference co-organized by Gustave Roussy and Dana-Farber, with support from Institut Servier. 2025 edition focused on radioligand therapies. The two institutions exchange expertise and conduct joint scientific programming, with co-presidents Dr Toni Choueiri (Dana-Farber) and Pr Karim Fizazi (Gustave Roussy).
• Elevate P.E. (Gustave Roussy International Egypt)flagshipOEM/ Whitelabel/ Licensing Partner · 8 April 2025Gustave Roussy International subsidiary signed a brand licensing agreement with Elevate P.E. to transform Dar Al-Salam-Hermel hospital in Cairo into Gustave Roussy International Egypt. Gustave Roussy contributes oncology expertise and training; Elevate P.E. equips and manages the facility; Egyptian government upgrades infrastructure. The center opened April 8, 2025, with 300+ bed capacity.
• DOSELIA European Consortium (CEA, Inserm, University of Caen Normandie, Centre François Baclesse, Aarhus University, Aarhus University Hospital, LMU Munich, West German Proton Therapy Centre Essen, Essen University Hospital)flagshipStrategic or Co-development Partner · 1 April 2025DOSELIA is a collaborative European research project coordinated by Gustave Roussy, using AI to improve pediatric radiotherapy by modeling overall patient radiation exposure and anticipating long-term risks. €944,000 from EU PIANOFORTE. Partners include CEA, Inserm, Aarhus University, LMU Munich, and others across France, Denmark, and Germany.
• Sofinnova PartnersflagshipStrategic or Co-development Partner · 18 March 2025Sofinnova Partners and Gustave Roussy announced the creation of Signadori Bio, an innovative cell therapy platform company created in collaboration with founders Dr Jean-Luc Perfettini and Pr Nathalie Chaput. This is the first biotech company emerging from the Sofinnova-Gustave Roussy strategic partnership.
• Université Paris-SaclayflagshipStrategic or Co-development Partner · 3 February 2025Gustave Roussy collaborates with Université Paris-Saclay on the 'Nouvelles frontières en cancérologie' interdisciplinary programme creating joint PhD theses and Master 2 internships. Also hosts the GRF-CRIS Clinical Scientist Emerging Leader Programme with the university. The President of the Republic laid the first stone of Gustave Roussy's new research building as part of the Paris Saclay Cancer Cluster.
• Guerbet, Intrasense, CHU d'AngerscoreStrategic or Co-development Partner · 3 December 2024Guerbet, Intrasense, Gustave Roussy, and CHU d'Angers obtained €5.9 million financing from Bpifrance for Liflow®, an innovative solution dedicated to oncological imaging. The project develops AI-powered imaging tools for cancer diagnosis and treatment planning.
• University Hospital ColognecoreStrategic or Co-development Partner · 27 November 2024University Hospital Cologne and Gustave Roussy launched Franco-German research project REDUCE-LUNG to improve outcomes for patients over 70 with advanced lung cancer. Project costs of EUR 1.5 million covered by a German donor and the French Oddo family.
• Cancer Core EuropecoreStrategic or Co-development PartnerGustave Roussy participates in Cancer Core Europe, a network of leading European cancer research centers facilitating clinical trial collaboration, knowledge exchange, and shared research infrastructure.

Scale indicators17 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Memorial Sloan Kettering Cancer Center: U.S. cancer-only specialty hospital and research institute consistently ranked among the global top cancer centers. Direct peer to Gustave Roussy in scope (comprehensive oncology care, research, education, liquid biopsy, AI-driven diagnostics, international brand).
• MD Anderson Cancer Center: University of Texas-affiliated comprehensive cancer hospital, consistently ranked #1 globally in oncology. Comparable to Gustave Roussy as an integrated clinical, translational research, and education institution serving high patient volumes across all tumor types.
• Dana-Farber Cancer Institute: Harvard-affiliated cancer research and treatment institute with which Gustave Roussy co-hosts the annual Transatlantic Exchange. Direct peer in specialty oncology clinical care, translational research, and clinical trial sponsorship.
• Charité – Universitätsmedizin Berlin: One of Europe's largest university hospitals and a partner in the Owkin-led pan-European agentic biology infrastructure. Strongly comparable as a European comprehensive oncology, research, and AI/biomedical data institution.
• The Royal Marsden NHS Foundation Trust: UK's leading comprehensive cancer center, focused exclusively on oncology diagnosis, treatment, research, and education. Direct peer in specialty cancer hospital scope, clinical trial activity, and integrated research-clinical model.
• Netherlands Cancer Institute (NKI): Dutch comprehensive cancer center combining hospital care and research under one roof. Listed among Gustave Roussy's European partnerships; comparable in scale, mission, and integrated research-clinical care model.
• Karolinska Institutet / Karolinska University Hospital: Swedish medical university and affiliated university hospital with leading oncology programs and Cancer Core Europe membership. Comparable as a European research-intensive oncology center with international patient services.
• Vall d'Hebron Institute of Oncology (VHIO): Barcelona-based oncology research institute and consortium partner on the EGL-001 Horizon Europe trial. Direct peer in translational oncology research, clinical trial sponsorship, and precision oncology.
• Istituto Europeo di Oncologia (IEO): Milan-based comprehensive cancer center focused exclusively on oncology prevention, diagnosis, treatment, and research. Comparable as a European specialty oncology hospital with integrated research and clinical programs.

Emerging players

• Cambridge Cancer Centre: University of Cambridge-affiliated cancer research center with significant translational and early-phase trial activity. Comparable to Gustave Roussy in research intensity and clinical trial pipeline, though with less scale on the inpatient hospital side.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights8 records

Customer concentration

• Xx.com/gustaveroussy
• YouTubeyoutube.com/@GustaveRoussyVideo
• Facebookfacebook.com/gustave.roussy
• LinkedInlinkedin.com/company/39072
• Instagraminstagram.com/gustave_roussy

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Gustave Roussy